Desai Neil 4

What Happened

• Neil Desai, a director of Whitehawk Therapeutics, was granted 38,040 derivative shares (an option award) on June 12, 2026. The grant price reported is $0.00, so the filing shows no cash paid at grant; this is an award of a derivative equity instrument rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-12; Filing date: 2026-06-15 (filed within normal insider reporting window).
• Instrument: Derivative (option award) — 38,040 shares granted at $0.00 per share (transaction code A = award/grant).
• Reported dollar value at grant: $0 (no cash paid at time of grant).
• Vesting (footnote): 100% of the option vests on the earlier of (i) the one-year anniversary of the grant date (June 12, 2027) or (ii) the day immediately before the next annual meeting of stockholders, provided Desai remains a Service Provider per the 2021 Equity Incentive Plan.
• Shares owned after transaction: Not disclosed in the provided filing details.
• Timeliness: Filing appears timely (filed three days after the transaction).

Context

• This was a grant of a derivative award (option) — not an exercise or sale. The grant itself does not produce immediate proceeds; any future value depends on vesting, potential exercise, and the stock price at that time.
• For retail investors, grants to directors are common as compensation and retention tools; they are informative about incentives but do not by themselves indicate buying or selling of stock.